BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Rhea-AI Summary

BioLineRx to Release Audited Financial Results for 2023 on March 26, 2024, Hosting Conference Call with CEO Philip Serlin at 08:30 a.m. EDT

- Management to Hold Conference Call at 08:30 a.m. EDT -

TEL AVIV, Israel, March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

The Company will host a conference call at 08:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until March 28, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside. 

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  

Contacts:

United States
John Lacey
BioLineRx
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo - https://mma.prnewswire.com/media/2154863/4165445/BioLineRx_Ltd_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2023-annual-financial-results-on-march-26-2024-302094450.html

SOURCE BioLineRx Ltd

FAQ

When will BioLineRx release its audited financial results for the year ended December 31, 2023?

BioLineRx will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

Who will be featuring remarks in the conference call hosted by BioLineRx ?

The conference call hosted by BioLineRx will feature remarks by Philip Serlin, Chief Executive Officer.

How can one access the conference call hosted by BioLineRx ?

To access the conference call, one can dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally, or visit the event page on the Company's website for a live webcast and replay.

Until when will the dial-in replay of the conference call be available?

The dial-in replay of the conference call will be available until March 28, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.